Sosei Group Co., Ltd.
Eisai Receives $10 Million Milestone in Inflammatory Disease Drug Discovery Collaboration with AbbVie
A global leader in structure-based drug discovery (“SBDD”) and development of G protein-coupled receptors (“GPCRs”), the AbbVie Group, a global biopharmaceutical company, is pleased to announce ) has reached an important research milestone in its drug discovery collaboration targeting inflammatory and autoimmune diseases. As a result, the Group will receive USD 10 million (approximately JPY 1,368 million*). The full amount of this milestone is expected to be recorded as sales in the fourth quarter of the fiscal year ending December 2022.
The Eisai Group and AbbVie entered into a drug discovery collaboration and license option agreement in 2020 with the aim of discovering, developing and commercializing novel small molecule drugs that act on GPCR targets selected by AbbVie. .
Under this agreement, the Group is entitled to receive up to US$32 million in total upfront payment and initial milestones, and up to US$377 million depending on the achievement of options, development and sales. In addition to these milestones, we are entitled to tiered royalties on global sales.
In addition, the Group and AbbVie have entered into a collaboration agreement in 2022 for the research, development and commercialization of novel medicines targeting multiple targets in neurological diseases. In addition, we are entitled to receive royalties on sales. Matt Burns, Group Head of Research and Development UK, said: “We are pleased to advance our promising collaborations with AbbVie in both inflammatory and neurological diseases. It’s a great example of how expertise drives programs forward, and we look forward to further progress and results from this partnership.”
*1 US dollar = 136.76 yen
About Sosei Heptares
The Eisai Group is an international global biotechnology company focused on the discovery and early development of new drug candidates generated from its proprietary StaR(R) technology targeting G protein-coupled receptors (GPCRs) and structure-based drug discovery (SBDD) technology. We are a biopharmaceutical company group. The Eisai Group is working to build a broad pipeline in multiple therapeutic areas, including neurological diseases, immunological diseases, gastrointestinal diseases, and inflammatory diseases.
So far, major global pharmaceutical companies such as AbbVie, AstraZeneca, Biohaven, Genentech (Roche Group), GSK, Kallyope, Neurocline, Novartis, Pfizer, Takeda Pharmaceutical Company Limited, Verily, etc. We partner with corporate and emerging biopharmaceutical companies. The Group is headquartered in Tokyo and has a research and development facility in Cambridge, UK.
“Sosei Heptares” is the corporate brand of Sosei Group Co., Ltd. (stock code 4565), which is listed on the Tokyo Stock Exchange. “Sosei”, “Heptares”, our group logo and StaR(R) are trademarks or registered trademarks of our group.
For more information, please visit our website https://soseiheptares.com/. LinkedIn: @soseiheptaresco
Details about this release: